Hims & Hers Health: Still An Undervalued Company With Tremendous Upside (NYSE:HIMS) | Seeking Alpha
HomeStock IdeasLong IdeasHealthcareSummaryHims & Hers Health remains deeply undervalued despite a 578% stock gain since 2022, with fundamentals vastly improved. HIMS is projected to reach $3. 5B revenue in. . .
HomeStock IdeasLong IdeasHealthcareSummaryHims & Hers Health remains deeply undervalued despite a 578% stock gain since 2022, with fundamentals vastly improved. HIMS is projected to reach $3. 5B revenue in 2026 and potentially $9B by 2030, driven by GLP-1 adoption, peptides, and international expansion. Insider and institutional ownership have increased, margins remain robust at 73%, and subscriber growth is accelerating, especially via the Novo partnership. My fair value estimate exceeds $100 per share by 2030, with current volatility and short interest presenting a compelling long-term buying opportunity. Orbon Alija/E+ via Getty ImagesWhen IcoveredHims & Hers Health (HIMS) back in June 2022, the stock was trading at $3. 69. Four years later, it stands at $25. 00, representing a massive 578% gain for long-term investors. Looking2. 86K FollowersAnalyst’s Disclosure:I/we have a beneficial long position in the shares of HIMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is for informational purposes only and is not intended as a recommendation. The information presented here is based on publicly available data, and I have no knowledge of your individual financial circumstances. It should not be construed as a recommendation or a solicitation to become a client of DocShah Financial, nor does it establish any advisory relationship between you, the reader, and DocShah Financial. It's important to note that conflicts of interest may exist, and I or my clients may have holdings in the stocks discussed and are subject to change at any time without prior notice. Any decision to invest should be based on your own research and consultation with a qualified financial advisor. Investing involves risks, and past performance is not indicative of future results. DocShah Financial or I may stand to gain from stock purchases, and readers should carefully consider their own risk tolerance and financial situation before making any investment decisions. You are fully responsible for any investment outcome. Seeking Alpha's Disclosure:Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.